{"disease":{"id":"prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease","name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}